Adjuvant targeted therapy for non-small cell lung cancer
Non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases with a wide range of possible targeted activating mutations. In this regard, a lot of attention is paid to such treatment of patients with NSCLC as adjuvant targeted therapy after radical surgical treatment, nowadays. The active...
Guardado en:
Autores principales: | Konstantin K. Laktionov, Aleksei M. Kazakov, Marat G. Gordiev, Pavel V. Kononets, Bakhrom B. Akhmedov, Julia N. Maevskaia |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
IP Habib O.N.
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1b1bd4636d484295a570f34b0f6e7870 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prospects for the development of adjuvant therapy for non-small cell lung cancer
por: K. K. Laktionov, et al.
Publicado: (2020) -
Adjuvant systemic therapy in older women with breast cancer
por: Leone J, et al.
Publicado: (2016) -
Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers
por: Hitomi Sumiyoshi Okuma, et al.
Publicado: (2021) -
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
por: Mo QG, et al.
Publicado: (2016) -
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
por: Tan AC, et al.
Publicado: (2021)